Navigation Links
Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
Date:1/3/2008

ANA598 demonstrates significant antiviral activity in vivo

SAN DIEGO, Jan. 3 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced preliminary data today from two studies of ANA598, a non-nucleoside inhibitor of the hepatitis C virus (HCV) NS5B polymerase, in a primate model of chronic HCV infection.

Two animals chronically infected with HCV genotype 1b each received once-daily oral doses of ANA598 at 30 mg/kg for four days. A rapid viral load decline was seen in both animals. At 48 hours (24 hours after the second dose), viral load declines were 2.2 and 2.6 log10 in the individual animals. In one animal the viral load reduction was sustained throughout the remaining dosing period, while in the second animal a modest rise in viral load was seen over days 3 and 4, although the rise observed (0.6 log10) was within the baseline variability seen in this animal prior to dosing.

In a previous study conducted to assess the pharmacokinetics (PK), safety, tolerability and preliminary antiviral activity of ANA598, two HCV genotype 1a infected animals received a single oral dose of ANA598 at 30 mg/kg. At 24 hours after dosing, plasma levels of ANA598 exceeded the replicon EC95 values. At 48 hours after dosing, the mean viral load decline in the two animals was 1.0 log10. ANA598 was well tolerated by all of the animals in both studies.

"These positive animal efficacy data reinforce our continued enthusiasm for development of ANA598 as a potential new direct antiviral treatment for chronic HCV," said Steve Worland, Ph.D., President and Chief Executive Officer of Anadys. "The rapid viral load decline and the favorable PK, safety and tolerability profile demonstrated in these animal efficacy stu
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
2. QuatRx Pharmaceuticals Announces Positive Phase 3 Results for Study of Ophena(TM) (ospemifene) to Treat Postmenopausal Vaginal Syndrome
3. Alseres Pharmaceuticals Initiates the ALTROPANE(R) POET-2 Phase III Clinical Trial Program
4. Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation
5. XTL Biopharmaceuticals Presents Data Regarding its Hepatitis C Virus Small Molecule Program at Hep Dart 2007 - an International Scientific Conference on Viral Hepatitis
6. Celator(R) Pharmaceuticals Reports CPX-351 Shows Anti-Cancer Activity in Leukemia Patients
7. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
8. Access Pharmaceuticals Demonstrates Ability to Significantly Reduce Glucose Levels in Pre-clinical Testing of Cobalamin(TM) Oral Insulin
9. Vion Pharmaceuticals To Present Preliminary Data on its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) at the American Society of Hematology Meeting
10. Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Stem Cell Transplantation
11. Sunesis Pharmaceuticals to Present Data on Two Product Candidates at the 49th Annual Meeting of the American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 2014 UBM Medica US announces that  ... to help oncologists and other clinicians gain a better ... of targeted therapies and immunotherapies, discusses some of the ... Every September, Blood Cancer Awareness Month ... about blood cancers—helping to increase survival rates and improve ...
(Date:9/19/2014)... 2014 According to market ... Mobile, Industrial, & Laboratory), Industry (Food, Pharmaceutical, Biotechnology, ... Rotary) & Geography - Global Trends & Forecast ... the lyophilization market on the basis of various ... of the market size of each of these ...
(Date:9/19/2014)... SAN DIEGO , Sept. 19, 2014 /PRNewswire/ ... industry leader in bioactive lipid-targeted therapeutics, announced today ... sell 3,605,042 registered shares of common stock and ... The combined purchase price for one registered share ... purchase one unregistered share of common stock will ...
Breaking Medicine Technology:OncoTherapy Network Highlights National Blood Cancer Awareness Month 2OncoTherapy Network Highlights National Blood Cancer Awareness Month 3OncoTherapy Network Highlights National Blood Cancer Awareness Month 4Lyophilization Market Worth $5,121.5 Million by 2019 2Lyophilization Market Worth $5,121.5 Million by 2019 3Lpath, Inc. Announces $12.5 Million Registered Direct Offering 2Lpath, Inc. Announces $12.5 Million Registered Direct Offering 3
... N.J., April 28, 2011 Savient Pharmaceuticals, Inc. (Nasdaq: ... presented at the European League Against Rheumatism (EULAR) 2011 Annual ... 28 in London, United Kingdom, and will feature the abstracts ... The first scheduled oral presentation and the poster session will ...
... April 28, 2011 Pharmasset, Inc. (Nasdaq: VRUS ... Healthcare Conference being held May 2 to 4, 2011 at ... America Merrill Lynch Healthcare Conference being held May 10 to ... Schaefer Price, Pharmasset,s President and Chief Executive Officer, will provide ...
Cached Medicine Technology:Savient Pharmaceuticals to Present Multiple Abstracts at The European League Against Rheumatism (EULAR) 2011 Annual Congress 2Pharmasset to Present at Two Upcoming Investor Conferences 2Pharmasset to Present at Two Upcoming Investor Conferences 3
(Date:9/19/2014)... disease, is caused by the bacterium Mycobacterium ... is a legal obligation to report the disease. ... and wasting among affected animals. The disease can ... animals produce less milk, exhibit fertility problems and ... udder inflammation. , To date there has ...
(Date:9/19/2014)... Lifeinsuranceprices.info has released a new blog ... insurance quotes online. , Clients who smoke or ... life insurance quotes from multiple providers on a single ... , Smoking will always influence life insurance prices, ... 50% more for life coverage and if they have ...
(Date:9/19/2014)... The Canton Group, Baltimore’s leading web development ... for the Xaverian Brothers. The new site aligns the Catholic ... edify one another through a life of Gospel witness lived ... manifest God’s care and compassionate love to the people of ... using a responsive web design, which allows users to easily ...
(Date:9/19/2014)... September 19, 2014 2014 Market ... a professional and in-depth research report on Kinesio ... including its definition, classification, application, and industry chain ... covers the international market analysis, including China’s domestic ... macroeconomic environment & economic situation analysis. The report ...
(Date:9/19/2014)... Outsourcing services provider Profit By RPO has ... conglomerate to provide HR outsourcing services in India. , " ... partner and will act as a talent acquisition and transformation ... 120 personnel across 3 locations in India in the next ... is a significant win for us and we are delighted ...
Breaking Medicine News(10 mins):Health News:Lymphatic fluid used for first time to detect bovine paratuberculosis 2Health News:Smokers Can Compare Term Life Insurance Quotes At Lifeinsuranceprices.info! 2Health News:Xaverian Brothers Partner with The Canton Group to Launch New Website 2Health News:Kinesio Tape Industry Analysis for North America, Europe, Asia & ROW Key Company Market Status Now at LifeScienceIndustryResearch.com 2Health News:Kinesio Tape Industry Analysis for North America, Europe, Asia & ROW Key Company Market Status Now at LifeScienceIndustryResearch.com 3Health News:Profit By RPO Bags huge RPO contract from US-based Implementation Partner 2
... Year, LIVINGSTON, N.J., Dec. 7 MM2 ... its wholly-owned subsidiary,Genotec Nutritionals, Inc., a New York ... distribution of its branded products and,through custom formulations ... strategic venture to manufacture sofgel capsules in Zhongsan,City, ...
... heart disease, ... Gary Stanton., MELBOURNE, Fla., Dec. 7 Heart Savior, (http://www.heartsavior.com ... one Natural product. Lowering unhealthy cholesterol levels is a good,start, but ... in the arteries and the heart muscle itself. The formulators of,Heart ...
... Conn., Dec. 7 Alexion,Pharmaceuticals, Inc. (Nasdaq: ALXN ... (PNH), as well as to Soliris(R),(eculizumab), a treatment for ... Society of Hematology Meeting, December 8 - 11 in ... a poster session on red,cell regulation and disorders of ...
... Dec. 6 Inverness Medical,Innovations, Inc. (Amex: ... rapid,diagnostic products for the consumer and professional markets, ... RBC Capital Markets Healthcare,Conference being held December 12, ... Ron Zwanziger, Chief Executive Officer, and Jon Russell, ...
... Effort is part of the ,Holidays at Mariners Inn - ... Friday, December 7, 2007 at 5:30 p.m. ,These men ... Dec. 6 Homeless men from the,Mariners Inn shelter and ... needy families this holiday season. The men will kick off,their ...
... The American Dietetic,Association welcomes and supports changes announced ... to the nation,s Special Supplemental,Nutrition Program for Women, ... the foods included in the WIC program more ... young children., "These changes are the most ...
Cached Medicine News:Health News:MM2 Group Establishes New Venture for Sofgel Manufacture in China 2Health News:MM2 Group Establishes New Venture for Sofgel Manufacture in China 3Health News:New Health Corp. Introduces Heart Savior(TM), the Ultimate Natural Heart Health Product 2Health News:Alexion Pharmaceuticals to Present Data on Soliris(R) (Eculizumab) and PNH at the 2007 American Society of Hematology (ASH) Annual Meeting 2Health News:Inverness Medical Innovations to Participate at 2007 RBC Healthcare Conference on December 12, 2007 2Health News:Detroit Homeless Men Adopt Local Families for Christmas 2Health News:American Dietetic Association Supports USDA's New WIC Food Packages 2
Malaria Pf. Assay Range...
An immunochromatographic rapid test for the detection of Plasmodium falciparum in whole blood....
... Uni-Gold™ Pf Malaria Test is a ... presence of Plasmodium falciparum ... an antigen-capture assay detecting presence of ... protein II (PfHRP- II), which is ...
High sensitive, specific one step immunochromatographic assay for human infectious disease...
Medicine Products: